Search Results

Your search for Syed Ali Abutalib, MD and Farhad Ravandi, MD,Syed Ali Abutalib, MD and Farhad Ravandi, MD matches 2 pages

Showing 1 - 2

By Syed Ali Abutalib, MD and Farhad Ravandi, MD / November 10, 2022

Newly Diagnosed AML: Induction to Maintenance

When it is dark enough, you can see the stars.” —Ralph Waldo Emerson Low-intensity therapy for older or unfit patients with acute myeloid leukemia (AML) was introduced in the early 2000s in the form of low-dose cytarabine or hypomethylation therapy (azacitidine or decitabine). Recent studies...

leukemia

By Syed Ali Abutalib, MD, and Farhad Ravandi, MD / June 10, 2021

Update on Clinical Trials in Acute Myeloid Leukemia

To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on acute myeloid leukemia (AML), such as the use of venetoclax added to...

Apr

Today In Oncology

Search Results

Your search for Syed Ali Abutalib, MD and Farhad Ravandi, MD,Syed Ali Abutalib, MD and Farhad Ravandi, MD matches 2 pages

Newly Diagnosed AML: Induction to Maintenance

Update on Clinical Trials in Acute Myeloid Leukemia

Adjuvant Pembrolizumab in Renal Cell Carcinoma: Overall Survival in KEYNOTE-564

Combined ICI and VEGF Inhibitor Trials in Cancer Cardiovascular Eligibility Criteria and Adverse Event Reporting

Risk of T-Cell and Second Primary Malignant Neoplasms After CAR T-Cell Therapy

Lack of Research Focused on Older Adults With Cancer May Be Contributing to Disparities in Care

Breast Cancer Survivors: Relationship Satisfaction and Emotional and Physical Well-Being